SCHEMBL17460433

SCHEMBL17460433

Cc1ccc(S(=O)(=O)OCC(COS(=O)(=O)c2ccc(C)cc2)Cc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
CA12 O43570 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
ATM Q13315 1/20 0.45
CA9 Q16790 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GAA P10253 1/20 0.45
MCHR1 Q99705 1/20 0.43
ALDH1A1 P00352 3/20 0.43
CTSL P07711 1/20 0.41
CNR2 P34972 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
VDR P11473 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18857832 0.93 CA2 (0.44) CA2CA7BCHEACHECA12
SCHEMBL6153740 0.92 GAA (0.44) CA2CA7BCHEACHECA12
SCHEMBL6155810 0.90 GAA (0.44) CA2CA7GAAALDH1A1CTSL
SCHEMBL4756032 0.88 CA2 (0.47) CA2CA7BCHEACHECA12
SCHEMBL10203187 0.87 GAA (0.50) CA2CA7BCHEACHECA12
SCHEMBL21378598 0.85 GAA (0.49) CA2CA7BCHEACHECA12
SCHEMBL7933300 0.85 GAA (0.49) CA2CA7BCHEACHECA12
SCHEMBL7925816 0.85 GAA (0.49) CA2CA7BCHEACHECA12
SCHEMBL4596569 0.85 ALDH1A1 (0.53) BCHEACHECA12CYP1A2CYP3A4
SCHEMBL19725071 0.84 CA2 (0.44) CA2CA7BCHEACHECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3994125-B1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMA (US) 2025-12-24 EP disclosed
EP-3578578-B1 BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS DOW GLOBAL TECHNOLOGIES LLC (US) 2025-07-02 EP disclosed
US-20240299402-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-09-12 US disclosed
US-11957687-B2 Modulators of HSD17B13 and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2024-04-16 US disclosed
US-20230094341-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2023-03-30 US disclosed
EP-3994125-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF Regeneron Pharmaceuticals, Inc. (US) 2022-05-11 EP disclosed
WO-2021003295-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-01-07 WO disclosed
EP-3578578-A1 BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS Dow Global Technologies Llc (US) 2019-12-11 EP disclosed
US-9975975-B2 Bis-biphenylphenoxy catalysts for polymerization of low molecular weight ethylene-based polymers DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-22 US disclosed
EP-3172250-A1 BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS Dow Global Technologies Llc (US) 2017-05-31 EP disclosed
US-20170137550-A1 BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS DOW GLOBAL TECHNOLOGIES LLC 2017-05-18 US disclosed
US-20170137550-A1 BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS DOW GLOBAL TECHNOLOGIES LLC 2017-05-18 US disclosed
WO-2016014749-A1 BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS DOW GLOBAL TECHNOLOGIES LLC (US) 2016-01-28 WO disclosed
WO-2016014749-A1 BIS-BIPHENYLPHENOXY CATALYSTS FOR POLYMERIZATION OF LOW MOLECULAR WEIGHT ETHYLENE-BASED POLYMERS DOW GLOBAL TECHNOLOGIES LLC (US) 2016-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299402-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF HSD17B3, HSD17B11, HSD17B1 CA2 3930/4885CA7 4297/4885BCHE 1985/4885
US-20230094341-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF HSD17B3, HSD17B11, HSD17B1 CA2 3930/4885CA7 4297/4885BCHE 1985/4885
US-11957687-B2 Modulators of HSD17B13 and methods of use thereof HSD17B3, HSD17B11, HSD17B1 CA2 3930/4885CA7 4297/4885BCHE 1985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.